Clazosentan

Unassigned

New Medicines

Pivlaz · Prevention of delayed cerebral ischaemia due to cerebral vasospasm associated with aneurysmal subarachnoid haemorrhage (SAH)

Information

Pivlaz
New molecular entity
Idorsia
Idorsia

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Endothelin receptor antagonist
aSAH accounts for approximately 5% of all strokes. A 2019 meta-analysis estimated aSAH incidence to be 8.3 per 100,000 person-years in Europe [6].
Prevention of delayed cerebral ischaemia due to cerebral vasospasm associated with aneurysmal subarachnoid haemorrhage (SAH)
Intravenous